Cargando…
DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma
Progestin resistance limits the effectiveness of progestin therapy in endometrial carcinoma for patients who desire to preserve fertility. To investigate the molecular mechanism of progestin resistance in endometrial carcinoma, we performed microarray analysis among Ishikawa and progestin resistant...
Autores principales: | Zhou, Qing, Li, Wenzhi, Kong, Deshui, Liu, Zhiming, Shi, Zhengzheng, Ma, Xiaohong, Li, Yongmei, Jiang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675747/ https://www.ncbi.nlm.nih.gov/pubmed/31215145 http://dx.doi.org/10.1002/cam4.2317 |
Ejemplares similares
-
Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma
por: Wei, Lina, et al.
Publicado: (2023) -
Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line
por: Li, Wenzhi, et al.
Publicado: (2019) -
LncRNA‐ZXF1 stabilizes P21 expression in endometrioid endometrial carcinoma by inhibiting ubiquitination‐mediated degradation and regulating the miR‐378a‐3p/PCDHA3 axis
por: Kong, Deshui, et al.
Publicado: (2021) -
Endogenous Dach1 in cancer
por: Wu, Kongming, et al.
Publicado: (2015) -
DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden
por: Riggs, McKayla J., et al.
Publicado: (2020)